Lenox Wealth Advisors’s Sage Therapeutics SAGE Stock Holding History

Lenox Wealth Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25	Closed	-$1K	–	956
2021 Q4	$1K	Buy	+25	New	+$1.05K	﹤0.01%	903

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Lenox Wealth Advisors's SAGE Position: Q1 2022 in Review

Lenox Wealth Advisors sold out of Sage Therapeutics (SAGE) in Q1 2022, closing a stake of 25 shares — an estimated $1K sold.

Lenox Wealth Advisors first reported a position in SAGE in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 211 funds tracked by Wall St. Rank hold SAGE as of Q1 2022.

Lenox Wealth Advisors reported no remaining Sage Therapeutics position as of Q1 2022 after selling out during the quarter.
Lenox Wealth Advisors sold 25 Sage Therapeutics shares in Q1 2022, an estimated $1K.
Lenox Wealth Advisors first reported a position in Sage Therapeutics in Q4 2021 and held it in 1 quarter.
Lenox Wealth Advisors's Sage Therapeutics position peaked at $1K in Q4 2021.
211 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.